ARCHIVES

Amgen Pays $24.9 Million To Settle Kickback Charges

This article is from The Cancer Letter archive.

Vol. 39 No. 16 | April 19, 2013

Download PDF Visit The Full Archive

Related Articles

Study: CYP2D6 Genotypes Are Unreliable Predictors of Benefit

March 30, 2012

Afinitor and Sutent Approved For Pancreatic Neuroendocrine Tumors

May 27, 2011

ODAC Okays Photofrin for Obstructive Esophageal Cancer

September 23, 1994

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

December 2, 1983

The NCI director and acting FDA commissioner called for faster approval of cancer drugs in speech to FDA staff.

October 21, 2005

Vaccine Increases PFS by 4 Months In Phase II Per-Protocol Analysis

June 27, 2014